olaparib
merck,astrazeneca
['pcsm', 'olaparib']
 presenting very intriguing data on the phase 1 combination of lu-psma and parp inhibitor olaparib. amazing psa90 of 44% and orr of 78%. intermittent dosing likely will be more tolerable for our patients. hopefully more to come! #asco2023 #pcsm - 
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.